期刊
GASTROENTEROLOGY RESEARCH AND PRACTICE
卷 2013, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2013/236963
关键词
-
资金
- National Natural Science Foundation of China [81270515, 81101579, 81072005, 81172312]
- Shanghai Science and Technology Foundation [11430702400]
- Chinese Foundation for Hepatitis Prevention and Control
- WBN Research Foundation [20100021]
- Shanghai Municipal Health Bureau Foundation [2011287, 2012107]
Background. Many studies have found that the antibiotic rifaximin is effective for the treatment of hepatic encephalopathy. However, there is no uniform view on the efficacy and safety of rifaximin. Methods. We performed a meta-analysis through electronic searches to evaluate the efficacy and safety of rifaximin in comparison with nonabsorbable disaccharides. Results. A total of 8 randomized controlled trials including 407 patients were included. The efficacy of rifaximin was equivalent to nonabsorbable disaccharides according to the statistical data (risk ratio (RR): 1.06, 95% CI: 0.94-1.19; P = 0.34). Analysis showed that patients treated with rifaximin had better results in serum ammonia levels (weighted mean difference (WMD): -10.63, 95% CI: -30.63-9.38; P = 0.30), mental status (WMD: 0.32, 95% CI: 0.67-0.03; P = 0.07), asterixis (WMD: 0.12, 95% CI: 0.31-0.08; P = 0.23), electroencephalogram response(WMD: -0.21, 95% CI: -0.34--0.09; P = 0.0007), and grades of portosystemic encephalopathy (WMD: -2.30, 95% CI: -2.78--1.82; P < 0.00001), but only the last ones had statistical significance. The safety of rifaximin was better than nonabsorbable disaccharides (RR: 0.19, 95% CI: 0.10-0.34; P < 0.00001). Conclusion. Rifaximin is at least as effective as nonabsorbable disaccharides, maybe better for the treatment of hepatic encephalopathy. And the safety of rifaximin is better.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据